Semaglutide ya Type 2 Diabetes

Semaglutide ndi m'badwo watsopano wa GLP-1 (glucagon-like peptide-1) analogues, ndipo semaglutide ndi mawonekedwe anthawi yayitali omwe amapangidwa kutengera kapangidwe ka liraglutide, yomwe imakhala ndi zotsatira zabwino pochiza matenda amtundu wa 2. Novo Nordisk yatha maphunziro a 6 Phase IIIa ya jekeseni wa semaglutide, ndipo adapereka ntchito yatsopano yolembera mankhwala kwa jekeseni wa semaglutide mlungu uliwonse ku US Food and Drug Administration (FDA) pa December 5, 2016. A Marketing Authorization Application (MAA) inaperekedwanso ku European Medicines Agency (EMA).

Poyerekeza ndi liraglutide, semaglutide ili ndi unyolo wautali wa aliphatic komanso kuwonjezeka kwa hydrophobicity, koma semaglutide imasinthidwa ndi unyolo waufupi wa PEG, ndipo hydrophilicity yake imakula kwambiri. Pambuyo pa kusinthidwa kwa PEG, sikungangomanga pafupi ndi albumin, kuphimba malo a enzymatic hydrolysis a DPP-4, komanso kuchepetsa kutuluka kwa aimpso, kutalikitsa theka la moyo, ndikukwaniritsa zotsatira za kufalikira kwa nthawi yaitali.